The use of targeting antibodies against CD47 are currently under development for the treatment of AML and MDS,81, 82 with demonstrated efficacy in combination with azacitidine including in patients with TP53‐mutant AML who are generally refractory to standard therapies. This evidence concerns the gene TP53 and acute myeloid leukemia.